fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Goserelin acetate

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Zoladex · DIN 02049325 · 3.6 mg · Depot injection

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Zoladex · DIN 02049325 Manufacturer: TerSera Therapeutics LLC; listing date 1996-10-01 Health Canada: Marketed since 2018-02-28 · brand ZOLADEX · ATC L02AE03 GOSERELIN · form Implant · route Subcutaneous · ingredients GOSERELIN (GOSERELIN ACETATE) 3.6 MG · company Tersera therapeutics llc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zoladex: Formulary list price $422.68 per unit (the source does not state the unit; exact figure $422.6778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02049325)

Source record
DIN 02049325: Zoladex Raw flags: sec3=Y Item: 100000069; group id 166; item number 0281; lccId None; manufacturer id TRS Source form: Depot Inj; strength: 3.6mg Recorded listing: General benefit Source prices (unrounded): $422.6778; ministry $422.6778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02049325 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16216
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049325
Shortage record checked October 6, 2026

Zoladex LA · DIN 02225905 · 10.8 mg · Depot injection

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Zoladex LA · DIN 02225905 Manufacturer: TerSera Therapeutics LLC; listing date 1996-12-19 Health Canada: Marketed since 2018-02-28 · brand ZOLADEX LA · ATC L02AE03 GOSERELIN · form Implant · route Subcutaneous · ingredients GOSERELIN (GOSERELIN ACETATE) 10.8 MG · company Tersera therapeutics llc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zoladex LA: Formulary list price $1204.73 per unit (the source does not state the unit; exact figure $1204.7322). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02225905)

Source record
DIN 02225905: Zoladex LA Raw flags: sec3=Y Item: 100000110; group id 166; item number 0282; lccId None; manufacturer id TRS Source form: Depot Inj; strength: 10.8mg Recorded listing: General benefit Source prices (unrounded): $1204.7322; ministry $1204.7322 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02225905 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43433
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225905
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L02A, L02AE): coverage varies; not interchangeable

  • Buserelin (Suprefact Depot 2 Months): general benefit
  • Leuprolide (Lupron Depot PDS): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, not a benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

LEUPROLIDE ACETATE

· 11 products · General benefit · strengths: 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg, 3.75mg/Vial, 22.5mg/Vial, 45mg · Inj-Kit, Pd for Inj - Vial Pk, Pd Susp Inj-Pref Syr Kit

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endometriosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEUPROLIDE ACETATE LEUPROLIDE ACETATE · General benefit LUPRON DEPOT (leuprolide acetate) Page 5 of 97 Unclassified / Non classifié Endometriosis LUPRON DEPOT 3.75 mg (1-Month) and 11.25 mg (3-Month) are indicated for: • the treatment of endometriosis, including pain relief and reduction of endometriosis lesions, for a period of six months. PM: https://pdf.hres.ca/dpd_pm/00082398.PDF; date 2025-11-13; DIN 00836273; fetched 2026-09-10 Product monograph • the treatment of endometriosis, including pain relief and reduction of endometriosis lesions, for a period of six months. LUPRON DEPOT with norethindrone acetate 5 mg daily is indicated for the initial management of endometriosis and for management of recurrence of symptoms. PM: https://pdf.hres.ca/dpd_pm/00082398.PDF; date 2025-11-13; DIN 00836273; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ZOLADEX® (goserelin acetate) is indicated for a number of hormone-dependent conditions as shown below under the headings Prostate Cancer, Breast Cancer and Benign Conditions: Prostate Cancer  ZOLADEX is indicated for the palliative treatment of patients with hormone- dependent advanced carcinoma of the prostate (Stage M1 according to the Tumour- Node-Metastasis [TNM] classification system or Stage D2 according to the American Urologic Association [AUA] classification).  ZOLADEX is indicated for use in combination with a non-steroidal antiandrogen and radiation therapy for the management of locally advanced (T3, T4) or bulky Stage T2b, T2c carcinoma of the prostate. Treatment with ZOLADEX and a non- steroidal antiandrogen should start 8 weeks prior to initiating radiation therapy and continue until completion of the radiation therapy.  ZOLADEX as adjuvant hormone therapy to external beam irradiation for patients with locally advanced prostate cancer (Stage T3-T4). Breast Cancer  ZOLADEX is indicated as an alternative to standard adjuvan… https://pdf.hres.ca/dpd_pm/00042728.PDF PM date: December 21, 2017 Source product: ZOLADEX; DIN 02049325; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18